N@N

Cerus to Release First Quarter 2011 Results on April 28, 2011

  //health-fitness.news-articles.net/content/2011/ .. first-quarter-2011-results-on-april-28-2011.html
  Published in Health and Fitness on Tuesday, April 12th 2011 at 5:35 GMT by Market Wire

CONCORD, Calif.--([ BUSINESS WIRE ])--Cerus Corporation (NASDAQ:CERS) announced today that its first quarter and 2011 financial results will be released on Thursday, April 28, 2011, after the close of the stock market. The company will host a conference call and webcast at 4:15 p.m. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.

To access the live webcast, please visit the Investor Relations page of the Cerus web site at [ http://investor.cerus.com ]. Alternatively, you may access the live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549 (international).

A replay will be available on the companya™s web site, or by dialing 800-642-1687 (U.S.) or 706-645-9291 (international) and entering conference ID number 44950670. The replay will be available approximately three hours after the call through May 11, 2011.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See [ http://www.cerus.com ] for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.